(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 17.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.87%.
Adc Therapeutics Sa's revenue in 2025 is $77,246,000.On average, 1 Wall Street analysts forecast ADCT's revenue for 2025 to be $8,677,078,336, with the lowest ADCT revenue forecast at $8,677,078,336, and the highest ADCT revenue forecast at $8,677,078,336. On average, 1 Wall Street analysts forecast ADCT's revenue for 2026 to be $9,716,572,746, with the lowest ADCT revenue forecast at $9,716,572,746, and the highest ADCT revenue forecast at $9,716,572,746.
In 2027, ADCT is forecast to generate $14,647,421,229 in revenue, with the lowest revenue forecast at $14,647,421,229 and the highest revenue forecast at $14,647,421,229.